利索-全球专利检索

  1. 登录
  2. 注册
发明授权
CN101830985B 肠出血性大肠杆菌O157:H7Tir与Tccp的重组蛋白 失效 - 权利终止

肠出血性大肠杆菌O157:H7Tir与Tccp的重组蛋白
摘要：
本发明涉及肠出血性大肠杆菌O157:H7转位紧密粘附素受体(Tir)与内膜素受体偶联细胞骨架蛋白(TccP)重组蛋白的制备方法及应用，属于生物技术领域。取tir和tccp基因C端序列串联克隆，获得pGEM-T-tir-tccp重组质粒，构建重组质粒pGEX-4T-1-tir-tccp，转化入感受态细胞BL21(DE3)中，获得重组菌株，经IPTG诱导后获得高效表达。本发明制备的重组蛋白Tir-TccP具有良好的免疫原性，可诱导机体产生高滴度的保护性抗体。Tir-TccP可作为研制亚单位疫苗的候选多价融合蛋白，为预防和治疗肠出血性大肠杆菌O157:H7感染提供了技术平台和防控手段。
摘要（英）：

The invention belongs to the field of biotechnology and relates to a preparation method and application of a recombination protein of enterohemorrhagic Escherichia coli O157:H7Tir and Tir couple cytoskeleton protein (Tccp). The preparation method comprises the steps of: connecting sequences at the C ends of the genes of tir and tccp for cloning to obtain a recombination plasmid of pGEM-T-tir-tccp; constructing a recombination plasmid of pGEX-4T-1-tir-tccp, and converting into a competent cell BL21 (DE3) to obtain a recombination strain; and introducing by IPTG to achieve high-efficiency expression. The recombination protein Tir-Tccp has good immunogenicity, and can induce an organism to generate a high-titre protective antibody. Tir-Tccp can be used as a candidate multivalent fusion protein for developing subunit vaccines and provides a technology platform and a prevention and control means for preventing and treating the infection of enterohemorrhagic Escherichia coli O157:H7.

公开/授权文献
0/0